The North American West Nile virus (WNV) epizootic, which began in 1999, has caused significant morbidity and mortality in horses. Because experimental infection has failed to consistently produce encephalitis in inoculated horses, investigation of naturally occurring cases was used to optimize strategies for diagnosis of this disease. Although WNV RNA could be detected by reverse transcriptase-polymerase chain reaction (RT-PCR) performed on whole blood collected from both clinically affected horses and unaffected herdmates, the diagnostic sensitivity of this approach was low compared with IgM-capture enzyme-linked immunosorbent assay. In addition, it was observed that 18.5% of herdmates of clinically ill horses seroconverted to WNV yet exhibited no overt clinical signs of WNV encephalitis. West Nile viral RNA was detected in neural tissue of 46 of 64 dead horses that were suspected of having WNV encephalitis. Some of these animals were IgM negative or had not been tested serologically. A primary cause of death other than WNV encephalitis was identified in 15 of the 64 cases, whereas the final diagnosis for 3 of these cases remains unresolved. Quantitative RT-PCR analysis of neural tissue from WNV RNA-positive horses demonstrated that the medulla contained the highest mean concentration of viral RNA and that WNV RNA could be detected in samples extracted from formalin-fixed neural tissue. A comparison of WNV RT-PCR amplification strategies found that nested RT-PCR improved diagnostic sensitivity only slightly over a single round of amplification and that a quantitative (TaqMan) assay had sensitivity and specificity that were equivalent to those of nested amplification.
West Nile virus (WNV) was introduced into North America in 1999. 1 This arbovirus is in the Japanese encephalitis antigenic complex of the genus Flavivirus, family Flaviviridae. 14 Since introduction into the United States, WNV has spread rapidly throughout the eastern and midwestern regions of the country and has caused significant morbidity and mortality in avian and mammalian species. The WNV epizootic has been particularly severe in horses, with numerous clinical cases and mortality rates of 35% or more. 16, 17 The presence of clinically evident neurological signs is compatible with, but not specific for, a diagnosis of equine WNV encephalitis. Thus, numerous differential diagnoses must be considered when WNV encephalitis is suspected. In living horses, diagnostic confirmation generally relies on evidence of recent seroconversion, but it is difficult to completely exclude the possibility of concurrent seroconversion in a patient with some other neurological disease. In mortally affected horses, postmortem findings will typically reduce the list of differentials to potential viral etiologies, but histological lesions of viral encephalitis are also not specific for WNV. Also, as with antemortem diagnosis, evidence of IgM antibodies in serum indicates exposure of the horse to WNV but does not confirm that this virus is the cause of concurrent disease.
Diagnosis of WNV in horses is currently based on observation of compatible clinical signs, such as ataxia, paresis, paralysis, hyperesthesia, muscle fasciculations, seizures, or fever 5, 16, 17, [21] [22] [23] and on one or more of the following: isolation or reverse transcriptasepolymerase chain reaction (RT-PCR) detection of WNV from tissue, blood, or cerebrospinal fluid (CSF); a 4-fold increase in plaque reduction neutralization test (PRNT) antibody titers between paired serum samples taken 2 weeks apart; detection of IgM antibody to WNV by IgM-capture enzyme-linked immunosorbent assay (ELISA) or a neutralizing titer of Ͼ1:10 by PRNT in a single serum sample. However, widespread use of a WNV vaccine coupled with multiple years of natural exposure may make interpretation of PRNT serological results less definitive. Currently, a presumptive diagnosis can be made when a horse with clinical signs is located in a county where WNV has been confirmed in some population (mosquito, bird, human, or horse) within the calendar year and where one of the previous tests was positive, or with a positive PCR test for WNV RNA in tissue, blood, or CSF or a positive immunohistochemistry for WNV antigen. 17 To date, experimental inoculations have been unsuccessful in consistently producing clinical disease in horses. 2, 3, 20 Thus, naturally occurring cases provide an important opportunity to develop and optimize strategies for antemortem and postmortem diagnosis of equine WNV encephalitis. In this study, a combination of serology, histopathology, and molecular methods was used to investigate antemortem and postmortem cases of suspected WNV encephalitis in horses. Analysis of the results has provided novel insight into diagnostic strategies for WNV encephalitis in horses and is useful in laboratory settings without the high-biosafety-level facilities recommended to pursue viral isolation.
Materials and methods
Case records. Test results and patient information were retrieved by searching information from computerized case records and submission files of the University of Missouri Veterinary Medical Diagnostic Laboratory. Positive cases were recorded between July and November, 2002. Horses with lymphocytic or granulomatous inflammation of the brain or spinal cord (from cases submitted before 2002) or those that had another confirmed diagnosis (from 2002) were used as negative controls in RT-nested PCR (RT-nPCR) and quantitative RT-PCR testing. For cases in which brain was a diagnostic specimen, the histological specimens were reviewed to select appropriate anatomical locations for retrospective RT-nPCR and quantitative RT-PCR testing. The areas of brain and spinal cord were identified according to external anatomical landmarks. 6 IgM-capture ELISA. A specific IgM-capture ELISA was performed as described previously. 13 Briefly, microtiter plate wells a were coated overnight with affinity-purified anti-equine IgM b in 0.05 M bicarbonate buffer (pH 9.6) at 4 C. Plates were washed with 0.01 M phosphate-buffered saline (PBS) (pH 7.4) containing 0.5% Tween 20 (PBST) and then blocked for 30 min at 37 C with PBST ϩ 5% nonfat dry milk. Plates were washed, 50 l of horse serum (diluted 1:400 in PBST) was added to duplicate wells, and plates were incubated for 1 hr at 37 C. After washing, 50 l of WNV antigen c or 50 l of BHK-21 control antigen c was then added to test and control wells and incubated for another hour at 37 C. After washing, 50 l of antiflaviviral immunoperoxidase conjugate c was added and incubated for an additional hour at 37 C. After the final wash, 50 l of 3,3Ј,5,5Ј-tetramethybenzidine (TMB) b was added. The reaction was stopped after 10 min with acidified TMB stop solution. b The plates were read on an ELISA plate reader at 450 nm. The absorbance value of the wells with WNV was divided by the absorbance values of the BHK-21 control antigen for an ELISA value. Samples were considered positive when absorbance values were Ն2-fold higher than those for the antigen control values. Positive control equine serum was obtained from the National Veterinary Services Laboratory, Ames, IA. d RNA extraction. Extraction of RNA from unfixed diagnostic samples (stored for short periods at 4 C or for longer periods at Ϫ80 C) was performed using either a phenol-guanidinium isothiocyanate reagent e or silica membrane spin columns f according to the manufacturer's instructions. Extraction of RNA from formalin-fixed, paraffin-embedded samples (2 sections per paraffin block, 20 m thick for each section) was performed by first deparaffinizing the samples with 2 extractions of xylene (1 ml per extraction), followed by centrifugation. Tissue pellets were then washed twice with 1 ml of 100% ethanol and dried for 10 min at room temperature. The tissue pellet (estimated to be equivalent to approximately 15-25 mg wet tissue weight) was then incubated in 0.25 ml buffer alanine aminotransferase g with proteinase K g for 3 hr at 55 C. Extraction of RNA was then performed according to the manufacturer's instructions, e and the final pellets were resuspended in 15 l RNase-free dH 2 O. For extraction of unfixed and fixed tissues, negative control extractions were performed concurrently with extractions of diagnostic samples.
Reverse transcriptase-polymerase chain reaction and RT-nPCR amplification. For RT-PCR and RT-nPCR amplification, previously reported oligonucleotide primers 9 were used; however, the amplification methods were modified as follows. Amplification of RNA was performed with the Qiagen One-Step RT-PCR kit. g For each sample, 2 l of RNA was added to 0.8 l One-Step RT-PCR enzyme mix in the manufacturer's buffer containing 2.5 mM MgCl 2 and 0.2 mM (each) deoxynucleoside triphosphates (dNTPs) in a final reaction volume of 20 l. Thermocycling was performed in a Perkin-Elmer 9700. h Thermocycling conditions were 50 C (40 min), 95 C (12 min), followed by 12 cycles of denaturation (95 C, 30 sec), annealing (70 C, 30 sec), and extension (72 C, 90 sec), with the annealing temperature in these cycles reduced by 1 C per cycle. An additional 38 cycles of denaturation (95 C, 30 sec), annealing (56 C, 30 sec), and extension (72 C, 90 sec) were performed followed by a final extension at 72 C for 7 min. Primers used for first-round amplification were (forward) 5Ј-ACCAAC-TACTGTGGAGTC-3Ј; (reverse) 5Ј-TTCCATCTT-CACTCTACACT-3Ј as reported previously. 9 Each primer was used at a final concentration of 1.0 M. First-round amplification of WNV RNA produced a 445-bp fragment from the envelope protein gene. Second-round (''nested'') amplification was performed using 0.5 l of the first-round amplification product with the Qiagen HotStarTaq PCR kit, g using the manufacturer's buffer containing 1.5 mM MgCl 2 and 0.2 mM (each) dNTPs in a final reaction volume of 20 l. Thermocycling was performed in a Perkin-Elmer 9700. h Thermocycling conditions were 95 C (12 min), followed by 12 cycles of denaturation (95 C, 30 sec), annealing (70 C, 30 sec), and extension (72 C, 90 sec) with the annealing temperature in these cycles reduced by 1 C each cycle. An additional 35 cycles of denaturation (95 C, 30 sec), annealing (56 C, 30 sec), and extension (72 C, 90 sec) were performed, followed by a final extension at 72 C for 7 min. Primers used for second-round amplification were (forward) 5Ј-GCCTTCATACACACTAAAG-3Ј and (reverse) 5Ј-CCAATGCTATCACAGACT-3Ј, as previously reported by Johnson et al. 9 Each primer was used at a final concentration of 1.0 M. Second-round amplification produced a 248-bp fragment. Amplification products (10 l) were observed in a 2% agarose, 1ϫ TAE gel by ethidium bromide staining and ultraviolet transillumination. 18 Synthesis of heterologous competitor RNA. Competitor RNA, which contained the WNV RT-PCR primer-binding sites flanking an unrelated internal sequence, was synthesized to allow quantitation of viral RNA in a quantitative (TaqMan) RT-PCR assay. To amplify DNA template for heterologous competitor RNA synthesis by in vitro transcription, oligonucleotide primers specific for the plasmid vector pUC19 were synthesized with 5Ј extensions. The forward and reverse primers for WNV competitor RNA template for use in a 5Ј exonuclease (TaqMan) RT-PCR assay were 5Ј-CACGTAATACGACTCACTATAGGTCAGC-GATCTCTCCACCAAAG-CTTCGCTATTACGCC-AG-3Ј and 5Ј-GTCTGGGTCAGCACGTTTGTCA-TTTACAACGTCGTGACTG-3Ј, respectively. The pUC19-specific region of each primer is underlined, the WNV-specific primer sequence is shown in bold, and the T7 RNA polymerase promoter-binding site is shown in italics. Amplification was performed with each oligonucleotide primer at a final concentration of 0.6 M with 1.0 unit HotStarTaq g in the manufacturer's buffer containing 1.5 mM MgCl 2 and 0.2 mM (each) dNTPs. Thermocycling was performed in a Perkin-Elmer 9700. h Conditions for first-round amplification were 95 C (12 min) followed by 10 cycles of denaturation (95 C, 30 sec), annealing (68 C, 20 sec), and extension (72 C, 30 sec), with the annealing temperature in these cycles reduced by 1 C for each cycle. An additional 25 cycles of denaturation (95 C, 30 sec), annealing (58 C, 20 sec), and extension (72 C, 30 sec) were performed, followed by a final extension at 72 C for 7 min. Amplification with pUC19 DNA as the template for PCR resulted in a 164-bp product. After PCR amplification, the reaction product was purified with the Qiaex II gel extraction kit g according to the manufacturer's instructions. The purified PCR product generated by amplification from pUC19 DNA was used as template for in vitro RNA transcription of heterologous competitor RNA, using the AmpliCap T7 High Yield Message Maker kit i according to the manufacturer's instructions. The 20-l (final volume) reaction was incubated at 37 C for 2 hr. After in vitro transcription, 1 unit of RNase-free DNase I was added, and the reaction mixture was incubated for an additional 15 min at 37 C. After DNase I digestion, the in vitro-transcribed RNA was purified using the RNeasy kit g and eluted in 100 l RNase-free dH 2 O. The concentration of the purified RNA was estimated by measuring the absorbance at 260 nm, and the purity was assessed by determining the ratio of absorbance at 260 nm to the absorbance at 280 nm. Samples were considered to be relatively pure and suitable for subsequent use as competitor RNA if that ratio was Ն2.0. After in vitro transcription, the RNA was serially diluted in RNase-free dH 2 O and stored as aliquots at Ϫ80 C. The number of molecules of competitor RNA per microliter was estimated based on the RNA concentration and the molecular weight of the transcript.
Quantitative (TaqMan) RT-PCR amplification. For quantitative RT-PCR amplification, a previously reported dual-labeled probe and oligonucleotide primers 12 were used with the following modifications. Amplification of 2 l RNA was performed in a 5Ј exonuclease (TaqMan) assay using the Qiagen QuantiTect Probe RT-PCR kit, g with thermocycling and detection performed in a Stratagene Mϫ4000. j Samples were analyzed in duplicate. Thermocycling conditions were 50 C (30 min), 95 C (15 min), followed by 40 cycles of denaturation (94 C, 15 sec) and annealing and extension (60 C, 60 sec). Primers used for the 5Ј exonuclease (TaqMan) WNV amplification were (forward) 5Ј-TCAGCGATCTCTCCACCAAAG-3Ј and (reverse) 5Ј-CTGGGTCAGCACGTTTGTCAT-3Ј, with the reverse primer modified slightly from that reported. 12 These primers correspond to base pair numbers 1160-1180 (forward primer) and 1211-1231 (reverse primer) of the WNV strain NY99 (GenBank accession number AF196835). The forward primer was used at a final concentration of 0.2 M, and the reverse primer was used at a final concentration of 0.4 M. Amplification of viral RNA produced a 72-bp fragment from the envelope protein gene. Amplification of WNV competitor RNA produced a 129-bp fragment. The dual-labeled probe used for detection of WNV template was 5Ј-6-FAM-TGCCCGACCATGGGAGAA-GCTC-BHQ1-3Ј. 12 The dual-labeled probe used for heterologous WNV competitor RNA template detection was 5Ј-HEX-TGTGCTGCAAGGCGATTAAGT TGGGT-BHQ2-3Ј. Probes k were used at a final concentration of 0.2 M. Known quantities of WNV competitor RNA (calculated from the optical density of the stock) were amplified to generate a standard curve for each run. The number of viral RNA copies in unknown samples was calculated from the cycle threshold and the equation for a straight line that was derived from the standard curve.
Results
Antemortem detection of WNV infection. From a population of over 500 horses in which WNV infection was suspected based on clinical signs, 5, 16, 17, [20] [21] [22] [23] RT-nPCR was performed on RNA extracted from ethylenediaminetetraacetic acid-anticoagulated blood of 140 horses. None of the 140 horses was previously vaccinated against WNV. Whole blood was collected at the same time as serum that was assayed by IgMcapture ELISA. Among these clinically affected horses, the majority (87%) were positive for IgM antibody but were RT-nPCR negative for WNV RNA (Table 1 , left column). Viral RNA was detected by RT-nPCR in a total of 18 (13%) of the blood samples from horses in this group. Most (15 of 18) of the RT-nPCR-positive samples were from horses that were concurrently IgM-capture ELISA positive. However, for 3 (2.1%) of the 140 clinically affected horses, only the WNV RT-nPCR on RNA extracted from whole blood was positive, and this was the sole laboratory confirmation of the diagnosis for these horses.
Additional whole-blood and serum samples were collected from 221 clinically normal, unvaccinated horses (representing 32 herds) in the immediate environment of clinically affected horses. Samples were tested also by both IgM-capture ELISA and RT-nPCR for WNV (Table 1 , right column). The animals came from herds of median size of 5 horses (range ϭ 1-51 horses); samples were drawn a median of 7 days (range ϭ 1-28 days) after the initial case was identified. A majority of these horses (78%; 173 of 221) were seronegative and RT-nPCR negative ( Table 1) . Of the 48 horses in which evidence of WNV infection was detected, most (77%) were IgM positive but RT-nPCR negative, and some (8.3%) were positive by both tests. However, in 14.6% (7 of 48) of these animals, evidence of WNV infection was detected only by RT-nPCR, which was the only identifier of WNV infection. The odds ratio of diagnosing infection only by detecting WNV RNA in whole blood from seronegative clinically normal horses versus clinically affected horses by RT-nPCR was 7.8 (95% confidence interval: 1.92-31.5) compared with all seropositive animals.
When all the 29 blood samples (listed in Table 1 ) that were positive by RT-nPCR were considered, 20 (69%) were positive after the first round of WNV RT-PCR. The 9 remaining samples were positive only after the second-round (nested) WNV PCR reaction. Quantitative RT-PCR was performed on 13 of the first round-positive samples chosen at random. The concentration of viral RNA detected in these 13 samples ranged from 10 2.4 to 10 4.4 viral RNA copies per milliliter of blood. For these samples, the analytical limit of detection was approximately 10 2.4 copies per milliliter of blood. There was no difference in the concentration of viral RNA detected in blood from clinically affected horses versus clinically normal herdmates.
Postmortem examination of horses with suspected WNV encephalitis. Postmortem examinations were performed on 64 horses in which WNV encephalitis was suspected, based on clinical signs, either by the owner or the referring veterinarian. Complete antemortem neurological evaluations were not performed on most horses. Some of the horses were found dead or in extremis by the owner before clinical evaluation. In 4 horses, the animal began exhibiting compatible clinical signs more than 4 wk before submission of tissue, and in 1 case, the animal was recovering when euthanatized for an unrelated cause. Fixed tissue only was submitted from 4 horses, and unfixed brain that was too autolyzed for microscopic examination was submitted from 4 horses. For analysis of the 64 cases (Table 2) , the horses were divided into 3 categories: 1) 46 cases in which neural tissue was positive for WNV RNA by either RT-nPCR or quantitative RT-PCR, 2) 15 cases in which neural tissue was negative for WNV RNA by the same methods and either another cause of death was found or lesions compatible with viral encephalitis were not identified in the central nervous system (CNS); and 3) 3 cases in which neural tissue was negative for WNV RNA, but the horses exhibited clinical signs and histological findings that were compatible with WNV infection. The animals involved were further subdivided as IgM positive, IgM negative, or WNV serological status undetermined.
In 46 of the 64 (71.9%) postmortem cases examined, WNV RNA was detected in neural tissue. Both RT-nPCR and quantitative RT-PCR failed to detect WNV RNA in samples extracted from myocardium, renal tissue, or lungs of 5 horses that were confirmed to contain WNV RNA in neural tissue. Although a majority of the WNV RNA-positive cases were also positive by IgM-capture ELISA, it is important to note that 17 of the 46 (37%) WNV RNA-positive horses either were IgM negative or were not tested by serology for WNV. For 3 of the WNV RNA-positive cases (1 IgM positive, 1 IgM negative, and 1 untested), advanced autolysis precluded histopathologic examination. Although RNA extracted from unfixed neural tissue was used for WNV detection in most horses, only fixed tissue was available for testing in 4 of the WNV RNA-positive cases. In 3 additional cases, RNA extracted from fresh tissue was negative for WNV RNA by both RT-nPCR and quantitative RT-PCR, whereas that extracted from fixed tissue was positive for WNV RNA by quantitative RT-PCR. Thus, fixed tissue was critical for detection of WNV in 7 of the WNV RNApositive cases investigated. To assess the specificity of quantitative RT-PCR testing on fixed tissue, RNA was extracted from 10 fixed tissue samples of horses with inflammatory neurological disease but was collected before the emergence of WNV in the Midwestern United States or had another confirmed diagnosis. All 10 of these control samples were negative for WNV RNA.
Horses in the second category were suspected of having WNV encephalitis as well. All were serologically negative or of unknown status. A cause of death not involving the CNS was established for 6 cases, and nervous system disease (either noninflammatory or without structural change) that was not compatible with WNV infection was detected in 4 others. The remaining 5 cases were of horses in which only brain was submitted for testing and inflammation was not identified by histopathology.
Three horses were placed in a third category. Each had histological lesions compatible with viral encephalitis yet were IgM negative to WNV (or not tested) and negative for WNV RNA. All 3 were found dead, suggesting a rapid clinical progression and presenting limited antemortem diagnostic testing options. Additional postmortem testing for these 3 cases failed to detect equine herpesvirus 1 or 4, eastern equine encephalomyelitis virus, or rabies virus.
Molecular detection of WNV RNA in neural tissue. For 9 cases in which WNV was detected by RT-nPCR, extraction of RNA was performed from both unfixed and formalin-fixed, paraffin-embedded neural tissue. When the concentrations of WNV RNA in paired samples (e.g., from the same anatomical region of the CNS) were compared by quantitative RT-PCR, extracts from unfixed tissue typically had greater concentrations (up to 10,000-fold higher) than RNA extracted from fixed tissue (Fig. 1) . Notably, 2 of the 9 samples were negative for WNV RNA in samples extracted from fixed tissue yet contained approximately 10 4 and 10 7 viral RNA copies per gram in unfixed tissue.
Different results were also obtained when 2 RNA extraction methods were compared using quantitative RT-PCR. A single homogenate was prepared for 14 unfixed neural tissue samples, and equal aliquots of each homogenate were extracted by a silica membrane spin column-based method or a phenolic-based extraction method. For each paired sample, higher concentrations of viral RNA were detected in the samples extracted by the phenolic-based method (Fig. 2) . The difference in viral RNA concentration ranged from 1.3-to 7.7-fold. One sample was WNV RT-PCR negative when extracted by the spin-column method, yet 155 viral RNA copies per 2 l were detected in the aliquot extracted by the phenolic-based method.
To resolve questions regarding bias due to differing regions of CNS submitted for testing, quantitative RT-PCR was used to assess WNV RNA concentration in neural tissue collected from various anatomic regions of unfixed brain and spinal cord from individual horses ( Table 3 ). In particular, the possibility of a false-negative diagnosis was assessed if no spinal cord or if only forebrain samples were submitted from field necropsy samples. The results demonstrated that for all 6 horses in which spinal cord samples were RT-PCR positive, WNV RNA could also be detected in brain. However, it is important to note that in 1 of 7 cases in which brain and spinal cord were both tested, the brain was positive for WNV RNA, yet the spinal cord did not have detectable concentrations of viral RNA. For the cases tested, concentrations of viral RNA ranged from a maximum of 10 9.1 RNA copies per g of tissue to a minimum concentration of 10 2.2 copies per g, which was the lowest analytical limit of detection. In each of the 12 cases, medulla and cerebrum were available for testing. When samples from these 2 areas were compared, the medulla generally had similar or higher concentrations of viral RNA compared with the cerebrum. In 4 cases (Nos. 3, 7, 9, and 11), viral RNA concentrations were about 100-fold higher in medulla than in cerebrum, and in case Nos. 7 and 9, viral RNA concentrations in the cerebrum approached the lower limits of detection. Three individual samples were negative, whereas samples from other regions of the CNS in the same horse had concentrations of viral RNA approximately 1,000-fold higher than the detectable limit. Analysis of multiple aliquots of 6 samples demonstrated approximate agreement in concentration values between replicates.
The diagnostic sensitivity and specificity of a single round of RT-PCR (i.e., nonnested) and quantitative RT-PCR were compared with nRT-PCR for detection of WNV RNA in unfixed neural tissue from 59 cases ( Table 4 ). In the 33 cases that were found to be positive by 2 or more of the RT-PCR assays, there was complete agreement between nRT-PCR and quantitative RT-PCR. A single round of RT-PCR failed to detect 1 of the WNV RNA-positive samples detected by the other 2 methods. All 3 methods correctly identified all 26 negative samples. Thus, the sensitivity and specificity of a single round of RT-PCR were 97% and 100%, respectively, compared with RT-nPCR, whereas both the sensitivity and specificity of quantitative RT-PCR were 100% compared with those of RT-nPCR.
Discussion
The great impact of WNV on horses during the first year of this virus' occurrence in Missouri allowed comparison of molecular methods and IgM-capture ELISA for confirming the diagnosis of WNV in living, clinically affected horses; subclinically affected horses; and suspected cases of fatal WNV encephalitis. Specifically, the usefulness of RT-nPCR and quantitative RT-PCR was investigated for each of these 3 populations. For antemortem detection of WNV infection, the IgM-capture ELISA was the mainstay of diagnosis: this test alone was used to confirm recent WNV infection in 548 encephalitic horses. Of 140 clinically affected horses for which both IgM-capture and RT-nPCR were performed, RT-nPCR provided evidence of WNV infection in a total of 18 horses, but only 3 of these horses were concurrently IgM negative. Thus, the diagnostic sensitivity of WNV RT-nPCR performed on whole blood of clinically affected horses was very low. However, an odds ratio analysis of making a diagnosis by RT-nPCR in clinically affected horses versus normal herdmates suggests that RT-nPCR was somewhat more consistent in detecting subclinically infected horses than in detecting encephalitic cases, possibly because an earlier time course of the infection was considered. It is important to point out that only a minor percentage of clinically normal RT-nPCR-positive cases were known to subsequently develop encephalitis. In 2 cases where clinically normal herdmates were re-bled, RT-nPCR-positive animals became negative during the period when IgM sero-conversion was observed. Collectively, these data demonstrated that RT-nPCR is capable of detecting viremia in WNV-infected horses either before or after seroconversion but that the presumed short duration and low viremic titer 3 contribute to a low prevalence of positive findings. In considering the seropositive rates of clinically normal herdmates, it is interesting to note that in this study the seropositive rate (18.5%) among unaffected herdmates of clinically ill horses was much higher than in previous reports from France, which found 8.3-8.5% of horses IgG positive and 3.6-4.8% IgM positive when all horses in the geographical area of the epizootic (i.e., not just horses in herds with clinical cases) were tested. 7, 15 In contrast to antemortem testing, RT-nPCR and quantitative RT-PCR were extremely helpful in postmortem detection of WNV infection, especially in establishing a diagnosis for horses that were found dead without previously observed clinical signs. A relatively high concentration of viral RNA was detected by quantitative RT-PCR in equine CNS samples, confirming the diagnosis of most cases of suspected WNV encephalitis, including a number of cases that were IgM negative or of unknown serological status. Also of interest in the present study is the inclusion of 5 horses that had been ill for prolonged periods of time yet had ample detectable virus. Only 1 of these 5 horses had improving clinical signs, and this animal died of intestinal volvulus.
Based on the results presented in this study, it was concluded that samples from brain, particularly brainstem and medulla, were adequate for WNV detection in encephalitic horses, and thus, the arduous work of spinal cord extraction during necropsy may not be necessary. A previous analysis of postmortem samples collected from naturally occurring cases of equine WNV encephalitis found that the lesion distribution was greater in the lower brain stem, 4 which would also suggest that this may be an important region of the CNS to sample in suspected cases of WNV encephalitis. Similarly, the brain stem, in general, and the medulla, specifically, have been identified as the regions of the CNS most involved in fatal cases of human WNV encephalitis. 19 Samples of CNS tissues from several cases in this study were found to have approximately 10 7 viral RNA copies per gram tissue, with concentrations in a few samples 10-fold higher. Although titrations of infectious virus for these samples would almost certainly have been lower than estimates of viral RNA concentrations as a result of defective interfering viral particles and incomplete genomic RNA replication, these values indicate that reasonably high levels of viral replication occur in CNS tissue of encephalitic horses. Previous direct comparisons have demonstrated that quantitative RT-PCR is capable of routinely detecting 0.1 infectious particle (expressed as plaque-forming units, PFU). 12 A recent investigation of experimentally infected corvid birds demonstrated infectious viral titers as high as 10 8.3 PFU/g of tissue were detected routinely. 10 Although few values have been published for mammalian species, virus titration of CNS tissue from a single experimentally infected encephalitic horse demonstrated a range of 10 4.0 -10 6.8 PFU/g of neural tissue. 3 In addition, quantitative RT-PCR demonstrated 1.1 ϫ 10 6 viral RNA copies/ml of CSF in a fatal case of human WNV encephalitis. 8 Given the dearth of information regarding quantitative aspects of natural WNV infection in mammalian hosts, future work is needed to define more clearly the roles of viral load and replication in encephalitic disease.
In addition to using unfixed neural tissue, RNA was extracted from sections of paraffin-embedded, formalin-fixed tissue, and WNV RNA was successfully amplified from the fixed tissue samples using quantitative RT-PCR. Based on unsuccessful attempts to amplify WNV from these samples using the nRT-PCR assay (unpublished data), it was reasoned that the small size (72 bp) of the quantitative RT-PCR product was an important factor for successful detection of WNV from fixed tissue. Comparison of quantitative RT-PCR results from the same areas of CNS demonstrated that concentrations of WNV RNA were consistently lower in samples extracted from fixed tissue than in unfixed (e.g., fresh or stored frozen at Ϫ80 C) samples. Fixed tissue was used to diagnose WNV encephalitis in 7 of the positive cases shown in Table 2 , several of which had tested negative previously for WNV RNA using unfixed neural tissue. The ability to detect WNV RNA in these 7 cases may be due to the availability of additional regions of the CNS (most importantly the medulla) for analysis. In addition, WNV infection has been shown to be focal in brain tissue of encephalitic crows, 11 and a focal infection might also explain inconsistent detection of WNV RNA in equine neural tissue from some cases. Thus, although fixed tissue may not be an optimal sample based on comparatively low extraction or amplification efficiency, it clearly can be used to make a diagnosis of WNV encephalitis in horses. Despite the potential disadvantages of fixed tissue as material for detection of WNV, use of fixed tissue may offer certain advantages such as reduced sample degradation that may occur during shipping of samples to a diagnostic laboratory. Although the kinetics of autolysis with respect to destruction of WNV particles in neural tissue is not known, it is reasonable to expect an appreciable decline in detectable viral concentration over time when tissues are held under conditions that permit autolysis.
Quantitative RT-PCR, in which only a single round of RT-PCR was performed in a TaqMan assay, was found to be equally sensitive and specific in the present study compared with nRT-PCR for detection of WNV RNA in CNS tissue. Thus, the characteristics of rapid detection coupled with high-sample throughput may make quantitative RT-PCR the method of choice for molecular detection of WNV for diagnostic laboratories that have this equipment. Direct experimental comparison of the results of a single round of standard RT-PCR with those of nRT-PCR demonstrated that second-round amplification resulted in only a slight increase in diagnostic sensitivity in RNA extracted from CNS tissue of horses infected with WNV, detecting only 1 additional positive sample. This result may to some extent reflect the relatively high concentrations of viral RNA found in many cases, as demonstrated by quantitative RT-PCR in this study. However, selection of amplification reagents and optimization of reaction conditions are also likely to be critical for successful detection of WNV RNA by a single round of RT-PCR (Kleiboeker et al., unpublished data). The ability to obtain accurate diagnostic results with a nonnested amplification protocol offers significant advantages. For example, nested amplification protocols increase the time and expense of diagnostic efforts and may also increase the possibility of false positives due to laboratory contamination with firstround product unless stringent measures are taken to prevent this occurrence (e.g., separate laboratories for first-and second-round reaction assemblies).
In a final set of comparisons, quantitative RT-PCR was also used to determine the concentration of viral RNA from aliquots of individual neural tissue samples extracted by 2 methods. For each CNS sample evaluated, the aliquots extracted using a phenolic-based method had greater detectable concentrations of viral RNA, as determined by quantitative RT-PCR, presumably because of the greater extraction efficiency of this method. In diagnostic testing, the method of extraction may not always affect the ability to detect WNV RNA because most neural tissue samples have reasonably high concentrations of viral RNA. However, data from this study indicate that some CNS samples have low concentrations of viral RNA, and thus, successful detection of WNV requires efficient methods of extraction and subsequent amplification.
In summary, antemortem and postmortem diagnosis of WNV encephalitis in horses was investigated. In clinically affected living horses and normal herdmates, a combination of serological and molecular methods was needed for antemortem detection of WNV infection, although RT-PCR was relatively inefficient for identifying new cases. For postmortem detection, multiple analyses were performed to assess the importance of the region of the CNS sampled, the effect of formalin fixation, and the importance of RNA extraction and subsequent amplification methods. The results of this study provide potential guidelines for future diagnostic efforts.
